AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01623856 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03258450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-behavioural intervention arm (PBI)
Description: The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
Study NCT02250391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPB-06
Description: 5 days continuous-infusion
Study NCT02250391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 days continuous-infusion
Study NCT00902512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment A
Description: Viagra® 100 mg tablet, administered with water single dose
Study NCT00902512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for the analysis of sildenafil in plasma
Description: Blood samples for the analysis of sildenafil in plasma
Study NCT00902512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Sildenafil 100 mg CT administered with water single dose
Study NCT00902512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood samples for the analysis of sildenafil in plasma
Description: Blood samples for the analysis of sildenafil in plasma
Study NCT00902512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Sildenafil 100 mg CT administered without water single dose
Study NCT01490333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: The vitamin D3 will be taken daily.
Study NCT01490333 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: The vitamin D3 will be taken daily.
Study NCT04693312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo medrol
Description: local injection
Study NCT01948323 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HEDUAfrica IT package+ standard care
Description: The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.~Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group.
Study NCT01435122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib Administration as outlined in Arm description
Study NCT02870218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smoking research cigarettes with e-cigarette
Description: Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
Study NCT02131389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Iconacy Hip System
Study NCT02721446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard
Description: Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke.
Study NCT02721446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incentive
Description: Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
Study NCT02721446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Salience
Description: Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me.
Study NCT02721446 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Incentive + Salience
Description: Combined message of incentive plus salience.
Study NCT01339845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ShanChol
Description: Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
Study NCT01339845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccine and behaviour
Description: Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
Study NCT01670708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE
Description: HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
Study NCT01670708 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Probation as Usual
Description: Probation officer supervises following standard protocols.
Study NCT00004056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00004056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Study NCT00004056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00004056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT00004056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00004056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Study NCT00004056 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00755391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavior therapy
Description: The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
Study NCT00755391 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Psychotherapy
Description: The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
Study NCT03202368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
Study NCT03294772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand sanitizer
Description: DCCs received alcohol-based hand sanitizer and a program educational.
Study NCT03294772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid soap
Description: DCCs received liquid soap and a program educational.
Study NCT04603274 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 8 sessions of electroacupuncture to the upper limb with carpal tunnel syndrome
Description: All participants will accept 8 sessions of electroacupuncture, 2 days a week for 1 month by experienced physicians. Acupuncture sterile disposable needles 0,25x 0,25 mm will be inserted for 20 minutes at specific acupuncture points to all patients. Electrical stimulation will be applied at specific acupuncture points for 20 minutes.
Study NCT02208505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine + Remifentanil-low dose
Description: single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
Study NCT02208505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil-high dose
Description: maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
Study NCT03440892 — intervention group
Intervention type: DRUG
Intervention: methotrexate
Description: folate antagonist
Study NCT03440892 — intervention group
Intervention type: DRUG
Intervention: sulfasalazine
Description: Immunomodulatory
Study NCT03440892 — intervention group
Intervention type: DRUG
Intervention: abatacept
Description: Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
Study NCT03440892 — intervention group
Intervention type: DRUG
Intervention: tocilizumab
Description: IL-6 receptor antagonist
Study NCT03440892 — intervention group
Intervention type: DRUG
Intervention: tofacitinib/baricitinib
Description: JAK inhibitor
Study NCT03973749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low salycilate diet
Description: Each arm of the experimental group will be exposed to low and high concentrations of dietary salycilates and urinary LTE4, FEV1, FVC, FEV1/FVC and total inspiratory nasal resistance will be measured at basal level and then two hours after each of the 3 daily meals.
Study NCT02656524 — intervention group
Intervention type: DRUG
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Product is used in accordance with SmPC
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pinaverium
Description: To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
Study NCT01641224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Atractylodes
Description: Atractylodes (\~10-15g)
Study NCT01641224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paeonia Lactiflora
Description: Paeonia Lactiflora (\~15-30g)
Study NCT01641224 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tangerine Peel
Description: Tangerine Peel (\~10g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ledebouriella Root
Description: Ledebouriella Root (\~10g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix codonopsitis
Description: Radix codonopsitis (\~10-15g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radix curcumae
Description: Radix curcumae (\~10g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingered citron
Description: Fingered citron (\~10g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tuckahoe
Description: Tuckahoe (15g)
Study NCT01641224 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is blindly given to patients.
Study NCT02474628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate
Study NCT02474628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Study NCT03968211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Salmonella typhi polysaccharide vaccine
Description: Salmonella typhi polysaccharide vaccine
Study NCT02329860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study NCT02329860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03846089 — intervention group
Intervention type: PROCEDURE
Intervention: Graft reperfusion
Description: antegrade (forward) or retrograde (backward) blood reperfusion of the liver graft
Study NCT04026646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation stretching exercise
Description: Proprioceptive Neuromuscular Facilitation stretching exercises (contract-relax-antagonist-contract method) will be performed 6 repetition and totally 30 seconds stretching for hamstring muscle group will be performed.It will be applied 3 days in a week for 8 week.
Study NCT04026646 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Static stretching exercise
Description: Static stretching exercises will be applied 2 repetition. Totally 30 seconds stretching for hamstring muscle group will be performed. It will be applied 3 days in a week for 8 week.
Study NCT01653756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPI-145, a PI3K Inhibitor
Description: Active drug
Study NCT01653756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IPI-145, a PI3K Inhibitor
Description: Active drug
Study NCT01653756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match IPI-145
Description: Comparator
Study NCT01653756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match IPI-145
Description: Comparator
Study NCT03413228 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: An interview to collect some informations will be done: demographic informations, medical history, vaccination against influenza status, symptoms and virological informations. Then, a nasal swab was performed in order to identified the influenza virus.
Study NCT02721654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148®
Description: Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution \& when administered intravenously it is a source of water, electrolytes \& calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water \& electrolytes or as an alkalinising agent.
Study NCT02721654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile \& non-pyrogenic solution \& is indicated for extracellular fluid replacement \& in the management of metabolic alkalosis in the presence of fluid loss, \& for restoring or maintaining the concentration of sodium \& chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailability (absorption) of the active components is complete (100 per cent).
Study NCT04251195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention
Description: Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
Study NCT04251195 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Intervention
Description: Participants will undergo 15 minutes of a cognitively challenging activity in the Virtual Reality environment. (More details about each condition will be added after study completion to protect the blinding of our participants).
Study NCT00622570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Description: 10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
Study NCT00622570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiopental
Description: 2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.~Maintenance: 3 mg/kg/h in perfusion
Study NCT03017833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03017833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Given PO
Study NCT03017833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Ancillary studies
Study NCT03017833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT01071369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: 0.5% Xylocaine
Study NCT01071369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine and Celestone
Description: non-particulate Celestone
Study NCT01397513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
Study NCT00004141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00004141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Study NCT00004141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor
Study NCT03037112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
Study NCT03037112 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Communication Skills
Description: The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
Study NCT04639505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: ELISA kit detecting the serum AMH level
Study NCT04639505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chemiluminescence
Description: CLIA method detecting the serum AMH level
Study NCT01952613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
Study NCT04255992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Arm
Description: 1000 mg Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study NCT04255992 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D/Calcium
Description: 1000 mg/800UI of the association Vitamin D/Calcium tablet / day will be added to the usual treatment for each patient for a period of 8 weeks.
Study NCT01427127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramosetron
Description: Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
Study NCT01427127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.